CompaniesImmatics Biotechnologies
Immatics Biotechnologies logo

Immatics Biotechnologies

active
Munich, Germany
Founded 2000
Website
About

Personalized T-cell Directed Immunotherapies

Areas of Focus

Categories

VaccineStem Cell & Cellular Therapy
Team (36)
Ali Mohamed
Senior Vice PresidentCMC
Immatics Biotechnologies
team_member
Andrea Mayer-Mokler
Vice PresidentGlobal Head of Clinical Sciences
Immatics Biotechnologies
team_member
Carsten Reinhardt
Chief Development Officer
Immatics Biotechnologies
team_member
Cedrik Britten
Chief Medical Officer
Immatics Biotechnologies
executive
Claudia Blattner
Vice President Business Development
Immatics Biotechnologies
executive
Claudia Wagner
Vice President TCR Research
Immatics Biotechnologies
executive
View all 36 team members →
Clinical Trials (11)
View all

Total Trials

11

As Lead Sponsor

7

As Collaborator

4

Total Enrollment

860

By Phase

PHASE1/PHASE2: 4PHASE1: 4PHASE2: 2PHASE3: 1

By Status

COMPLETED: 7RECRUITING: 2TERMINATED: 2
Clinical Trials Pipeline11 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
NCT00785122
NCT01222221
NCT01265901
NCT02054884
NCT05359445
NCT05958121
Hover over trial bars to see details

Recent Trials

NCT05958121Lead Sponsor
IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors
PHASE1/PHASE2Recruiting
145 participants
Started: Aug 9, 2023 · Completed: Sep 30, 2027
NCT05359445Lead Sponsor
IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor
PHASE1Recruiting
95 participants
Started: May 19, 2022 · Completed: Dec 31, 2029
NCT03203005Collaborator
IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients
PHASE1/PHASE2Completed
22 participants
Started: Sep 18, 2017 · Completed: Dec 20, 2019
NCT02149225Lead Sponsor
GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients
PHASE1Completed
16 participants
Started: Oct 31, 2014 · Completed: Jun 30, 2018
NCT02054884Collaborator
F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma
PHASE2Terminated
13 participants
Started: Oct 25, 2013 · Completed: Dec 15, 2017
View all 11 trials →
Locations (1)
Headquarters
Munich, Germany
Map

Loading map...